Vagina tissue - Medium Biopsy 1-3 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Histology of vaginal lesion.

₹370₹529

30% OFF

Vaginal Tissue - Medium Biopsy 1-3 cm

Why is it done?
- To obtain tissue samples from the vagina for histopathological examination and microscopic analysis
- To diagnose suspicious lesions, abnormal growth, or areas of concern identified during colposcopy or routine gynecological examination
- To evaluate for cervical intraepithelial neoplasia (CIN), dysplasia, carcinoma, or other malignant conditions
- To assess for benign conditions such as polyps, cysts, chronic inflammation, or infectious processes
- To determine the nature and extent of tissue pathology following abnormal Pap smear results or positive HPV testing
- Typically performed during colposcopy when abnormal epithelial changes or lesions require tissue confirmation
Normal Range
- Normal Result: Benign squamous epithelium with normal maturation and differentiation; no dysplasia, malignancy, or significant inflammation
- Negative for Malignancy: No evidence of invasive carcinoma or high-grade dysplasia; tissue architecture is preserved with normal cellular organization
- Specimen Size: Medium biopsy specimen measuring 1-3 cm in diameter, containing adequate tissue for diagnostic assessment
- Adequacy: Specimen must be adequately fixed, properly labeled, and contain sufficient tissue for complete histological evaluation
- Units: Tissue sample analyzed qualitatively; results reported as descriptive histopathological diagnosis
Interpretation
- Benign Findings: Normal squamous epithelium, chronic inflammation, benign polyps, cysts, or condyloma (genital warts) indicate non-malignant pathology
- Cervical Intraepithelial Neoplasia (CIN): CIN 1 (low-grade): Mild dysplasia with abnormal epithelial changes confined to lower third of epithelium CIN 2 (high-grade): Moderate dysplasia involving up to two-thirds of epithelium CIN 3 (high-grade): Severe dysplasia or carcinoma in situ with extensive epithelial involvement
- Invasive Carcinoma: Malignant cells invading through basement membrane into underlying stroma; indicates advanced cervical cancer requiring immediate treatment
- Infectious Processes: HPV changes, evidence of viral infection, bacterial infection, or parasitic infestation with associated tissue inflammation
- Factors Affecting Interpretation: Specimen fixation quality, tissue adequacy, presence of inflammation, previous treatments, HPV status, patient age, and hormonal factors influence pathological assessment
- Clinical Significance: Results directly influence treatment decisions, referral to oncology, surveillance protocols, and patient management strategies; CIN 2+ findings typically require excisional procedures
Associated Organs
- Primary Organs: Vagina, cervix, and lower reproductive tract; particularly the cervical epithelium which is the primary site of dysplasia and malignancy development
- Related Organ Systems: Female reproductive system including uterus, ovaries, and regional lymph nodes which may be involved in advanced cervical pathology
- Associated Medical Conditions: Cervical cancer, vaginal cancer, cervicitis, vaginitis, genital warts (HPV infection), benign polyps, cervical stenosis, and infectious diseases
- Diseases Diagnosed: Squamous cell carcinoma, adenocarcinoma, CIN 1-3, invasive cervical malignancy, and HPV-related premalignant lesions
- Potential Complications: Malignancy progression if high-grade dysplasia untreated; metastatic spread to lymph nodes, pelvis, or distant organs in invasive cancer; uterine involvement; fertility implications
Follow-up Tests
- For CIN 1 Findings: HPV testing; cytology follow-up at 12 months; repeat colposcopy; observation protocol typically recommended due to potential for regression
- For CIN 2-3 Findings: Excisional procedures (loop electrosurgical excision procedure/LEEP, cold knife conization); histological examination of excised margins; colposcopic follow-up at 4-6 weeks
- For Invasive Carcinoma: Staging studies (imaging, MRI, CT, PET); oncology referral; assessment for treatment options; pelvic lymph node evaluation
- For Benign Findings: Routine cervical cancer screening (Pap smear, HPV testing) at recommended intervals; treatment of underlying infection if present
- Complementary Tests: HPV genotyping, immunohistochemistry (p16/Ki-67), repeat Pap smear, colposcopy, endocervical assessment, and molecular testing
- Monitoring Frequency: CIN 1: Annual surveillance; CIN 2-3: Follow-up within 4-6 weeks post-treatment; Invasive cancer: Oncology-directed surveillance; Normal: Standard screening intervals per guidelines
Fasting Required?
- Fasting: No - Fasting is not required for vaginal tissue biopsy
- Patient Preparation: Avoid douching, tampons, and vaginal intercourse for at least 24-48 hours prior to procedure; urinate before the procedure; empty bladder for patient comfort
- Medications: Continue routine medications; anticoagulants should be discussed with provider if bleeding risk concerns exist; NSAIDs may be taken for pain management post-procedure if needed
- Special Instructions: Schedule procedure when menstruation is not expected; local anesthetic may be applied; brief discomfort is normal; expect mild cramping and spotting for 24-48 hours post-procedure; arrange transportation if sedation planned
- Specimen Handling: Tissue must be immediately placed in appropriate fixative solution (typically 10% neutral buffered formalin); label with patient identifiers; ensure proper chain of custody documentation

How our test process works!